Interview with MannKind’s CEO, Al Mann, and CFO, Matt Pfeffer.
October 23, 2013- Interviewed by Steven E. Greer, MD
The Healthcare Channel interviewed the CEO of MannKind, Al Mann, and the CFO, Matt Pfeffer. Topics discussed include the latest clinical trial data on inhaled insulin Afrezza and the cash situation. We also discuss Mr. Mann’s other company, Second Sight, which has a Medicare and FDA-approved bionic eye to treat diseases that damage the nerves in the retina.
Super rapid acting insulin and inhaled insulin
CMS Medicare Medicaid, Diabetes, Endocrinology, Late Breaking Data, Medical Devices, Tech reviews | apples49 | 
July 26, 2015 2:03 am
No Comments
No comments yet.
Notice: comments_rss_link is deprecated since version 2.5! Use post_comments_feed_link() instead. in /data/30/1/121/80/1121895/user/1185656/htdocs/wordpress/wp-includes/functions.php on line 3406
RSS feed for comments on this post.
